Pharmacologic biomarkers in the development of stratified cancer medicine

William Douglas Figg*, David R. Newell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate howPDbiomarkers can be powerful tools for guiding treatment strategies.We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine.

Original languageEnglish
Pages (from-to)2525-2529
Number of pages5
JournalClinical Cancer Research
Issue number10
StatePublished - 15 May 2014
Externally publishedYes


Dive into the research topics of 'Pharmacologic biomarkers in the development of stratified cancer medicine'. Together they form a unique fingerprint.

Cite this